Nul secures pre-seed to roll out telehealth naltrexone alcohol-reduction programme
This article covers Nul, a UK healthtech startup, which has raised £733,000 ($1m) in a pre-seed funding round to complete its commercial launch in the UK and prepare for international expansion. The funding will be used to scale product and clinical teams, accelerate customer acquisition and support a planned entry into the US market, targeting remote alcohol reduction treatment and people seeking discreet, evidence-based telehealth options.
Nul, a UK healthtech startup, has raised £733,000 ($1m) in a pre-seed funding round to finish its commercial launch in the UK and prepare for international expansion. The investment will be used to scale the product and clinical teams, accelerate customer acquisition and support a planned entry into the US market — a notable move for a telehealth service addressing alcohol reduction.
Why it matters
Alcohol use disorder and harmful drinking remain widespread yet under-served by modern digital treatment options. Nul’s early traction — more than 120 paying customers and an annualised revenue run rate above £300,000 from a summer 2025 UK test phase — suggests there is consumer demand for discreet, remote treatment models that combine clinical oversight with medication.
The funding comes as telehealth services for behavioural health and chronic conditions continue to attract attention from clinicians and entrepreneurs seeking scalable, privacy-friendly alternatives to traditional care pathways.
Inside the product
Nul provides a fully remote programme combining virtual consultations, behavioural support and prescription medication in a subscription-based telehealth model. At its core is naltrexone, a medication clinically established to reduce alcohol cravings by acting on reward pathways in the brain. The clinical approach is built around The Sinclair Method, a structured protocol that pairs medication with guided drinking reduction rather than demanding immediate abstinence.
The platform aims to centralise clinical supervision, digital guidance and prescription fulfilment to make evidence-based treatment more accessible and compatible with users’ everyday lives.
Who are the investors?
The pre-seed round was led by dmg ventures and BYVP, with participation from angel investors. The company raised £733,000 ($1m) and plans to complement institutional backing with a retail crowdfunding campaign hosted on Republic Europe to let individual investors participate in the next phase of growth.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Matus Maar, Founder and CEO of Nul, said:
Alcohol reduction remains one of the largest underserved areas in healthcare. Telehealth has transformed categories like weight loss and mental health, but alcohol treatment has lagged behind despite the scale of the problem. Our goal is to make evidence-based treatment accessible, discreet and compatible with real life.
Maar founded the company to offer an alternative route for people who want to cut down without committing to immediate abstinence, emphasising convenience and clinical oversight.
The bigger picture
Nul’s approach sits at the intersection of telehealth and pharmacologically assisted behavioural treatment, a space that has seen more activity in recent years as startups apply digital-first models to long-standing healthcare gaps. The use of subscription pricing and remote prescribing mirrors trends in weight-loss and mental health services that have scaled rapidly in the UK and beyond.
The company’s move to open a Republic Europe campaign also reflects broader fundraising trends where early-stage healthtech companies supplement institutional rounds with retail investment to broaden their supporter base.
This funding round and Nul’s planned expansion underline growing appetite among UK healthtech entrepreneurs to modernise treatment pathways and export those models abroad, particularly to larger markets such as the US where demand for remote treatment options remains high.
They've invested in Nul
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK